Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye Jun 3, 2008
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib Mar 18, 2008
OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection Feb 25, 2008
